Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
K-0009
NCT00116467
March 2001
January 2006
Name | Location |
---|---|
Johns Hopkins University | Baltimore, Maryland 21205 |
University of California, San Francisco | San Francisco, California 94143 |
Dana Farber Cancer Institute | Boston, Massachusetts 02115 |
University of Chicago | Chicago, Illinois 60637 |